Appaloosa Horse Club Approves EQUIOXX®, ULCERGARD® and GASTROGARD®

Organization offers FDA-approved options to members nationwide

DULUTH, GA — Starting Jan. 1, 2009, Appaloosa Horse Club (ApHC) members will be able to use EQUIOXX® (firocoxib), ULCERGARD® (omeprazole) or GASTROGARD® (omeprazole) prior to competition.

The decision by the ApHC Board of Directors provides thousands of horse owners nationwide with FDA-approved options for common diseases like equine osteoarthritis and stomach ulcers.

“I believe these products are great options to help us maintain the health of our equine partners,” says Frank Larrabee, president of the ApHC Board of Directors. “Personally, my own horses have experienced stomach ulcers and the need for NSAIDs, and I’m sure the thousands of Appaloosa members involved in equine activities are faced with the same concerns. We salute the efforts of the researchers who have helped make life a little easier on these horses.”

With the approval, EQUIOXX is the only nonsteroidal anti-inflammatory drug (NSAID) approved for use up to 14 consecutive days in the ApHC. EQUIOXX also is approved for use in the American Quarter Horse Association and United States Equestrian Federation.

EQUIOXX is the first equine oral NSAID to be approved in more than 20 years. It is proven to control joint pain and inflammation associated with equine osteoarthritis, which is one of the most common causes of lameness in horses. Also known as degenerative joint disease, osteoarthritis can develop in horses as young as 2 years old. EQUIOXX works quickly to provide 24 hours of pain relief and is easily administered as an oral paste.

The ApHC also approved GASTROGARD and ULCERGARD for use no more than 24 hours prior to competition. GASTROGARD and ULCERGARD are the first and only FDA-approved products for the treatment and prevention of equine stomach ulcers, respectively.

Horses can develop stomach ulcers in as little as five days, but GASTROGARD can treat stomach ulcers even while horses continue to train. Proactive use of ULCERGARD during short or long periods of time* can help reduce the risk of stomach ulcers in horses that regularly deal with stressful situations, such as training, traveling and competing.

“Equine osteoarthritis and stomach ulcers are common for horses of all breeds,” says Dr. Frank Hurtig, director, Veterinary Services, Merial. “Now, competitors in ApHC events can help ensure their horses have FDA-approved choices to help them address these diseases and enable their horses to compete at their best.”

For complete ApHC rules regarding the use of EQUIOXX, GASTROGARD and ULCERGARD, please visit

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,000 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see

Comments are closed.